Table 1.

Proliferation rate, measured by BrdU incorporation after treatment with imatinib, nilotinib and transfection with BCR-ABL siRNA or co-treatment of BCR-ABL siRNA with imatinib or nilotinib in tyrosine kinase inhibitor-sensitive and –resistant BCR-ABL oligoclonal cell lines.